NASDAQ · IPHA
Innate Pharma S.A. ADS
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IPHA: Nov 05, 2026
Innate Pharma S.A. ADS is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · The Motley Fool · MarketBeat- Fintel · Oct 27, 10:23 AM EDTInnate Pharma S.A. Announces PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027Innate Pharma S.A. announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The company stated that the revised timing reflects the event-driven nature of
- Zacks · Oct 8, 8:35 AM EDTDown 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a TurnaroundInnate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Zacks · Oct 5, 8:35 AM EDTDown 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Fintel · Oct 2, 7:44 AM EDTInnate Pharma S.A. – Depositary Receipt Price Target Increased by 27.91% to $8.22The average one-year price target for Innate Pharma S.A. – Depositary Receipt (NASDAQGS:IPHA) (MUN:IDDA) has been revised to $8.22 / share. This is an increase of 27.91% from the prior estimate of $6.43 dated September 13, 2026. These figures represent aggregate analyst targets c
- Zacks · Sep 23, 11:00 AM EDTInnate Pharma (IPHA) Upgraded to Buy: Here's What You Should KnowInnate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- The Motley Fool · Sep 17, 11:07 PM EDTInnate Pharma (IPHA) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Sep 17, 9:02 AM EDTInnate Pharma Q2 Earnings Call HighlightsInnate Pharma (NASDAQ:IPHA) said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab. Chief Execut
- RTTNews · Sep 17, 7:56 AM EDTInnate Pharma Reports H1 Loss Narrows; Advances Lacutamab And IPH4502(RTTNews) – Innate Pharma SA (IPH; IPHA), a clinical-stage biotechnology company developing immunotherapies for cancer, reported first-half 2026 financial results and provided a business update highlighting progress across its oncology pipeline.
- MarketBeat · Aug 14, 3:02 PM EDTInnate Pharma Secures €30M, Extends Cash Runway Into 2028Innate Pharma (NASDAQ:IPHA) said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs and its preclinical antibody-drug conjugate, or ADC, portfolio. Chief Executive
- NASDAQ.com · Aug 10, 8:29 AM EDTPre-Market Most Active for Aug 10, 2026 : SPCX, ACHR, ABCL, SION, INTC, IPHA, SLN, CHMI, NOK, HZO, B, IONQThe NASDAQ 100 Pre-Market Indicator is down -31.07 to 29,691.23. The total Pre-Market volume is currently 110,469,046 shares traded.The following are the most active stocks for the pre-market session: Space Exploration Technologies Corp. (SPCX) is +2.99 at $136.10, with 9,630,42
- RTTNews · Aug 10, 6:21 AM EDTInnate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO(RTTNews) – Shares of Innate Pharma S.A. (IPHA), a clinical-stage company, surge over 25% after the company announced a strategic partnership with Swedish Orphan Biovitrum AB (SOBI.ST) to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study of Lacutamab, an investigatio
- RTTNews · Aug 10, 3:10 AM EDTSobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma(RTTNews) – Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma, a key step toward filing for accelerated approval of lacuta
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Innate Pharma S.A. ADS from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.